Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress.

Cai W, Chong K, Huang Y, Huang C, Yin L.

Open source

DOI
10.1016/j.redox.2023.103010
Published
2023-12-27
Container
Redox Biol
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.redox.2023.103010,
  title = {Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress.},
  author = {Cai W and  Chong K and  Huang Y and  Huang C and  Yin L.},
  year = {2024},
  journal = {Redox Biol},
  doi = {10.1016/j.redox.2023.103010},
  url = {https://doi.org/10.1016/j.redox.2023.103010}
}

RIS

TY  - JOUR
TI  - Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress.
AU  - Cai W
AU  -  Chong K
AU  -  Huang Y
AU  -  Huang C
AU  -  Yin L.
PY  - 2024
JO  - Redox Biol
DO  - 10.1016/j.redox.2023.103010
UR  - https://doi.org/10.1016/j.redox.2023.103010
ER  -

APA

W, C., K, C., Y, H., C, H., & L., Y. (2024). Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress.. Redox Biol. https://doi.org/10.1016/j.redox.2023.103010

Source records